Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELOX Stock Price Chart Interactive Chart >
ELOX Price/Volume Stats
|Current price||$0.25||52-week high||$2.00|
|Prev. close||$0.27||52-week low||$0.21|
|Day high||$0.28||Avg. volume||226,660|
|50-day MA||$0.30||Dividend yield||N/A|
|200-day MA||$0.71||Market Cap||21.69M|
Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.
Most Popular Stories View All
ELOX Latest News Stream
|Loading, please wait...|
ELOX Latest Social Stream
View Full ELOX Social Stream
Latest ELOX News From Around the Web
Below are the latest news stories about Eloxx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELOX as an investment opportunity.
The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!
Investment analysts at Oppenheimer began coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a note issued to investors on Thursday, Price Targets.com reports. The brokerage set an outperform rating and a $4.00 price target on the stock. Oppenheimers price target suggests a potential upside of 441.27% from the stocks previous close. ELOX has been the 
Millennium Management LLC acquired a new position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 393,703 shares of the companys stock, valued at approximately $783,000. Millennium Management LLC owned approximately 0.82% of Eloxx Pharmaceuticals at the end of the 
Analysts expect that Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) will announce ($0.12) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Eloxx Pharmaceuticals earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.11). Eloxx Pharmaceuticals posted earnings per share of ($0.15) in the same 
State Street Corp reduced its holdings in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) by 56.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 189,203 shares of the companys stock after selling 248,516 shares during the quarter. State Street Corps holdings in 
ELOX Price Returns